Recent advances in AD pharmacology shifted towards targeting the pathomechanisms and progression of the disease: to this end, various monoclonal antibodies (i.e., aducanumab, lecanemab, and donanemab) have been studied, which act by inhibiting the formation of senile plaque via targeting APP [23,54,89]. This evidence concerns the gene APP and Alzheimer disease.